We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-11.64%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
-$306M
Cap. Flow
-$59.1M
Cap. Flow %
-5.47%
Top 10 Hldgs %
66.39%
Holding
80
New
21
Increased
8
Reduced
13
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
2
MRK icon
Merck
MRK
+$18.4M
3
ALGN icon
Align Technology
ALGN
+$11.1M
4
HRTX icon
Heron Therapeutics
HRTX
+$8.1M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.87M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
FATE icon
Fate Therapeutics
FATE
+$15.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEN icon
51
Compugen
CGEN
$212M
$2.18M 0.2%
+300,000
New +$2.36M
SAGE
52
DELISTED
Sage Therapeutics
SAGE
$2.14M 0.2%
+74,430
New +$4.31M
ACRS icon
53
Aclaris Therapeutics
ACRS
$715M
$1.99M 0.18%
1,911,573
– –
ZYME icon
54
Zymeworks
ZYME
$1.62B
$1.77M 0.16%
49,989
-57,563
-54% -$2.36M
BCRX icon
55
BioCryst Pharmaceuticals
BCRX
$2.42B
$1.63M 0.15%
815,690
-1,335,474
-62% -$3.68M
VYNE icon
56
VYNE Therapeutics
VYNE
$1.62M 0.15%
+168
New +$2.63M
APLS
57
DELISTED
Apellis Pharmaceuticals
APLS
$1.33M 0.12%
49,580
– –
MRSN
58
DELISTED
Mersana Therapeutics
MRSN
$1.31M 0.12%
+9,000
New +$1.57M
SYBX
59
DELISTED
Synlogic
SYBX
$989K 0.09%
38,331
– –
ZGNX
60
DELISTED
Zogenix, Inc.
ZGNX
$816K 0.08%
+32,983
New +$1.2M
FATE icon
61
Fate Therapeutics
FATE
$275M
$812K 0.08%
36,564
-598,579
-94% -$15.1M
ITCI
62
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$800K 0.07%
+52,005
New +$1.13M
PDSB icon
63
PDS Biotechnology
PDSB
$37.4M
$104K 0.01%
142,635
– –
APLT
64
DELISTED
Applied Therapeutics
APLT
– –
-134,825
Closed -$3.68M
HALO icon
65
Halozyme
HALO
$9.88B
– –
-72,481
Closed -$1.28M
MGNX icon
66
MacroGenics
MGNX
$233M
– –
-1,173,882
Closed -$12.8M
REGN icon
67
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-50,086
Closed -$18.8M
RYTM icon
68
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-21,319
Closed -$489K
XBIT icon
69
XBiotech
XBIT
$68.6M
– –
-240,995
Closed -$4.5M
ORTX
70
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-28,341
Closed -$3.9M
MRTX
71
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-108,383
Closed -$14M
SGEN
72
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-50,000
Closed -$5.71M
DRNA
73
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-159,512
Closed -$3.51M
ALXN
74
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-75,000
Closed -$8.11M
FTSV
75
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-138,643
Closed -$5.46M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2020 Portfolio in Review

As of Q1 2020, Sofinnova Investments held 80 positions worth $1.08B, down 22% from $1.39B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments withdrew a net $59.1M in Q1 2020, closing 16 positions and reducing 13 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Alexion Pharmaceuticals worth $27.6M.

  • Sofinnova Investments's largest Q1 2020 buy was Alexion Pharmaceuticals: 307,300 shares worth $27.6M.
  • Sofinnova Investments added most to Merck in Q1 2020, an estimated $18.4M increase.
  • Sofinnova Investments's biggest Q1 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.4M.
  • Sofinnova Investments fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $18.8M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $1.08B portfolio in Q1 2020.
  • Sofinnova Investments opened 21 new positions and closed 16 in Q1 2020.
  • Sofinnova Investments's portfolio value fell 22% quarter-over-quarter to $1.08B.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.